An ongoing dialogue on HIV/AIDS, infectious diseases,
January 29th, 2009
Too Many Options: What Actually Happened
We recently published a case in AIDS Clinical Care entitled “Too Many Options”, describing a patient with longstanding HIV infection, virologic failure, and resistance to NRTIs, NNRTIs, and PIs.
Fortunately, resistance and tropism testing gave him several options for a new drug regimen — including darunavir, etravirine, maraviroc, enfuvirtide, and — if one believes phenotypic NRTI susceptibility with multiple TAMs — several NRTIs.
And what did our three experts suggest? Three different regimens:
- Sharon Walmsley: darunavir/r, maraviroc, and etravirine (three drugs — not counting ritonavir)
- Tim Wilkin: darunavir/r, raltegravir, maraviroc, and tenofovir/FTC (five drugs)
- Graeme Moyle: darunavir/r, raltegravir, and maraviroc (three drugs, but different from Sharon’s selection)
Now these are smart, highly-experienced clinicians, physicians who are active in clinical research, know the literature extremely well, and actually see patients. (Funny how that last part is sometimes left out.) Each of them provided sound reasons for their (varying) choices.
And what did we do with this patient? (Or one very much like him … obviously some details changed as per HIPAA mandate.)
We offered him the chance to enroll in the clinical study ACTG 5241 (mentioned by Tim), which takes patients like this, gives them an optimal regimen — then randomizes them to receive or not to receive NRTIs.
(I don’t think it will ruin the study to mention that the “flip of the coin” gave him the “No Nukes” option.)
I sure hope we learn something from this study. While we know that regimens should contain “two (preferably three)” active agents, beyond that there’s plenty of uncertainty out there.
2 Responses to “Too Many Options: What Actually Happened”
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Borrelia burgdorferi Infection and Erythema Migrans January 15, 2026Expansion of the range of the lone star tick, a vector for southern tick-associated rash illness, has led to overlap with the range of the Lyme disease vector Ixodes scapularis, which may cause diagnostic uncertainty.
- Case 2-2026: A 63-Year-Old Man with Pulmonary Nodules, Liver Mass, and Vision Loss January 15, 2026A 63-year-old man was admitted to the hospital because of fever, cough, and vision loss in the right eye. He had pulmonary nodules, a liver mass, and multiple brain lesions. A diagnosis was made.
- Primary Palmoplantar Pustulosis January 15, 2026A 60-year-old man with a 30-pack-year smoking history presented with a 2-year history of a painful rash on his palms and soles. Numerous pustules with erosions, crusting, and surrounding erythema were noted.
- The Things We Carry January 15, 2026The ID, the pen, the epinephrine, the scalpel are the nonnegotiables, the necessities for any hospital shift. But they are not the only things a physician carries, and certainly not the most burdensome.
- Serogroup Switching in Neisseria meningitidis with Dual Antibiotic Resistance January 8, 2026Serogroup switching away from serogroup Y has been identified in the major ciprofloxacin-resistant Neisseria meningitidis strain, which may impede identification of ciprofloxacin-resistant cases of N. meningitidis infection.
- Borrelia burgdorferi Infection and Erythema Migrans January 15, 2026
Fortunately, we can choose from 5 active drugs outside of the NRTI class: boosted darunavir (only 2 primary mutations, 33f, 84v), maraviroc, raltegravir, and etravirine. While Fuzeon would also be effective, I would not use an injectable since we have more convenient oral options. This seems like an ideal situation for maraviroc since the virus is CCR5 tropic. I would add two other agents–boosted darunavir and etravirine, saving raltegravir as a back up in case of drug side effect, like etravirine rash.
What I’ve done with similar patients in my practice was to put them on:
1. etravirine
2. maraviroc
3. raltegravir
This adds up to 5 pills twice a day. The patient’s virus(es) has not been exposed to any of these drugs and you do not need to use a PI/r. This has worked great for my patients!